{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:16:14Z","timestamp":1794255374372,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Real-world data on treatment patterns and clinical outcomes for newer drugs, including integrase strand transfer inhibitors, among older people with human immunodeficiency virus (PWH) are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cohort study included PWH enrolled in the Veterans Aging Cohort Study (VACS) who were prescribed a standard 3-drug antiretroviral therapy (ART) regimen containing dolutegravir (DTG), bictegravir (BIC), cobicistat boosted elvitegravir (EVG), raltegravir (RAL), or darunavir\/ritonavir (DRV) plus 2 nucleoside reverse transcriptase inhibitors between January 1, 2014, and March 31, 2020, and who were \u226550\u00a0years at regimen initiation. The association between regimen and virologic effectiveness or discontinuation was assessed using logistic regression models with inverse probability of treatment weights. Pairwise comparisons were made between DTG-based regimen and each of the other 3-drug regimens, stratified by ART experience.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 15,702 PWH (across treatment groups, median age 58\u201362\u00a0years; 94\u201398% male; 5\u201311% Hispanic; 44\u201360% Black; 29\u201342% White), 5,800 received DTG-based regimens, 2,081 BIC-based regimens, 4,159 EVG-based regimens, 1,607 RAL-based regimens, and 2,055 received DRV-based regimens. Among ART-na\u00efve PWH, there were no statistical differences in the odds of virologic suppression, and 6- and 12-month discontinuations were higher in those on DRV. Among ART-experienced PWH, compared to DTG, those on RAL and DRV were less likely to be suppressed at 6\u00a0months (RAL vs DTG: aOR 0.64, 95% CI 0.51\u20130.81; DRV vs DTG: aOR 0.63, 95% CI 0.51\u20130.76) and those on EVG and DRV were less likely suppressed at 12\u00a0months (EVG vs DTG: aOR 0.82, 95% CI 0.68\u20130.99; DRV vs DTG: aOR 0.64, 95% CI 0.52\u20130.80). Those on DRV were more likely to have virologic failure within 12 months (aOR 1.96, 95% CI 1.30\u20132.97). Six- and 12-month discontinuations were higher in those on RAL and DRV, but less likely for BIC-based regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>DTG-based regimens demonstrated higher levels of effectiveness and durability compared to DRV- or RAL-based regimens and had similar treatment responses as BIC- and EVG-based regimens among ART-experienced older PWH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-024-00681-w","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T09:54:07Z","timestamp":1734774847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS)"],"prefix":"10.1186","volume":"21","author":[{"given":"Lei","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy E.","family":"Henegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsha S.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Justice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"2","key":"681_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","volume":"3","author":"DE Dow","year":"2014","unstructured":"Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Ther. 2014;3(2):83\u2013102. https:\/\/doi.org\/10.1007\/s40121-014-0029-7.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"681_CR2","doi-asserted-by":"publisher","first-page":"106343","DOI":"10.1016\/j.ijantimicag.2021.106343","volume":"57","author":"N Mbhele","year":"2021","unstructured":"Mbhele N, Chimukangara B, Gordon M. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents. 2021;57(5):106343. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106343.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"681_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/hiv.13125","volume":"22","author":"A Zhabokritsky","year":"2021","unstructured":"Zhabokritsky A, Szadkowski L, Burchell AN, et al. Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC). HIV Med. 2021;22(8):759\u201369. https:\/\/doi.org\/10.1111\/hiv.13125.","journal-title":"HIV Med"},{"issue":"2","key":"681_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/COH.0000000000000614","volume":"15","author":"A Richterman","year":"2020","unstructured":"Richterman A, Sax PE. Antiretroviral therapy in older people with HIV. Curr Opin HIV AIDS. 2020;15(2):118\u201325. https:\/\/doi.org\/10.1097\/COH.0000000000000614.","journal-title":"Curr Opin HIV AIDS"},{"key":"681_CR5","doi-asserted-by":"crossref","unstructured":"Dunn-Walters D, Martin V, Abdulla A. The immune system. In: Rai G, Abdulla A, editors. The biology of ageing. CRC Press; 2013. p. 35\u201349: chap 4.","DOI":"10.1201\/9781846197925-6"},{"issue":"3","key":"681_CR6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1172\/JCI64096","volume":"123","author":"E Montecino-Rodriguez","year":"2013","unstructured":"Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958\u201365. https:\/\/doi.org\/10.1172\/JCI64096.","journal-title":"J Clin Invest"},{"key":"681_CR7","doi-asserted-by":"publisher","first-page":"101471","DOI":"10.1016\/j.smim.2021.101471","volume":"51","author":"CW Cai","year":"2021","unstructured":"Cai CW, Sereti I. Residual immune dysfunction under antiretroviral therapy. Semin Immunol. 2021;51:101471. https:\/\/doi.org\/10.1016\/j.smim.2021.101471.","journal-title":"Semin Immunol"},{"issue":"11","key":"681_CR8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40266-021-00894-y","volume":"38","author":"E Vider","year":"2021","unstructured":"Vider E, Gavioli EM. Clinical safety considerations of integrase strand transfer inhibitors in the older population living with HIV. Drugs Aging. 2021;38(11):967\u201375. https:\/\/doi.org\/10.1007\/s40266-021-00894-y.","journal-title":"Drugs Aging"},{"issue":"2","key":"681_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","volume":"7","author":"A Chawla","year":"2018","unstructured":"Chawla A, Wang C, Patton C, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183\u201395. https:\/\/doi.org\/10.1007\/s40121-018-0201-6.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"681_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","volume":"15","author":"M Smit","year":"2015","unstructured":"Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(15)00056-0.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"681_CR11","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/phar.1670","volume":"35","author":"J Jourjy","year":"2015","unstructured":"Jourjy J, Dahl K, Huesgen E. Antiretroviral treatment efficacy and safety in older HIV-infected adults. Pharmacotherapy. 2015;35(12):1140\u201351. https:\/\/doi.org\/10.1002\/phar.1670.","journal-title":"Pharmacotherapy"},{"issue":"8 Suppl 2","key":"681_CR12","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1097\/01.mlr.0000223670.00890.74","volume":"44","author":"SL Fultz","year":"2006","unstructured":"Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a \u201cvirtual\u201d cohort using the National VA Health Information System. Med Care. 2006;44(8 Suppl 2):S25-30. https:\/\/doi.org\/10.1097\/01.mlr.0000223670.00890.74.","journal-title":"Med Care"},{"issue":"8 Suppl 2","key":"681_CR13","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/01.mlr.0000223741.02074.66","volume":"44","author":"AC Justice","year":"2006","unstructured":"Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care. 2006;44(8 Suppl 2):S13-24. https:\/\/doi.org\/10.1097\/01.mlr.0000223741.02074.66.","journal-title":"Med Care"},{"key":"681_CR14","doi-asserted-by":"publisher","unstructured":"Tate JP, Sterne JAC, Justice AC, Veterans Aging Cohort S, the Antiretroviral Therapy Cohort C. Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals. AIDS. 2019;33(5):903\u201312. https:\/\/doi.org\/10.1097\/QAD.0000000000002140.","DOI":"10.1097\/QAD.0000000000002140"},{"issue":"3","key":"681_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"issue":"28","key":"681_CR16","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379. https:\/\/doi.org\/10.1002\/sim.6607.","journal-title":"Stat Med"},{"issue":"6","key":"681_CR17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656\u201364. https:\/\/doi.org\/10.1093\/aje\/kwn164.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"681_CR18","doi-asserted-by":"publisher","first-page":"e18174","DOI":"10.1371\/journal.pone.0018174","volume":"6","author":"BK Lee","year":"2011","unstructured":"Lee BK, Lessler J, Stuart EA. Weight trimming and propensity score weighting. PLoS ONE. 2011;6(3):e18174. https:\/\/doi.org\/10.1371\/journal.pone.0018174.","journal-title":"PLoS ONE"},{"issue":"25","key":"681_CR19","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"issue":"3","key":"681_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/0962280210395740","volume":"22","author":"SR Seaman","year":"2011","unstructured":"Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2011;22(3):278\u201395. https:\/\/doi.org\/10.1177\/0962280210395740.","journal-title":"Stat Methods Med Res"},{"issue":"5","key":"681_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550\u201360. https:\/\/doi.org\/10.1097\/00001648-200009000-00011.","journal-title":"Epidemiology"},{"issue":"7","key":"681_CR22","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357\u201365. https:\/\/doi.org\/10.1016\/S2352-3018(18)30092-4.","journal-title":"Lancet HIV"},{"issue":"10107","key":"681_CR23","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(17)32299-7.","journal-title":"Lancet"},{"issue":"9936","key":"681_CR24","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"B Clotet","year":"2014","unstructured":"Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(14)60084-2.","journal-title":"Lancet"},{"issue":"10","key":"681_CR25","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1089\/AID.2020.0286","volume":"37","author":"S Mayer","year":"2021","unstructured":"Mayer S, Rayeed N, Novak RM, et al. INSTI-based initial antiretroviral therapy in adults with HIV, the HIV Outpatient Study, 2007\u20132018. AIDS Res Hum Retroviruses. 2021;37(10):768\u201375. https:\/\/doi.org\/10.1089\/AID.2020.0286.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"43","key":"681_CR26","doi-asserted-by":"publisher","first-page":"e13016","DOI":"10.1097\/MD.0000000000013016","volume":"97","author":"K Jacobson","year":"2018","unstructured":"Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naive human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: a retrospective cohort study. Medicine. 2018;97(43):e13016. https:\/\/doi.org\/10.1097\/MD.0000000000013016.","journal-title":"Medicine"},{"issue":"7","key":"681_CR27","doi-asserted-by":"publisher","first-page":"e1408","DOI":"10.1093\/cid\/ciaa1037","volume":"73","author":"H Lu","year":"2021","unstructured":"Lu H, Cole SR, Westreich D, et al. Clinical effectiveness of integrase strand transfer inhibitor-based antiretroviral regimens among adults with human immunodeficiency virus: a collaboration of cohort studies in the United States and Canada. Clin Infect Dis. 2021;73(7):e1408\u201314. https:\/\/doi.org\/10.1093\/cid\/ciaa1037.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"681_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/QAD.0000000000003069","volume":"36","author":"H Lu","year":"2022","unstructured":"Lu H, Cole SR, Westreich D, et al. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. AIDS. 2022;36(2):277\u201386. https:\/\/doi.org\/10.1097\/QAD.0000000000003069.","journal-title":"AIDS"},{"issue":"1","key":"681_CR29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","volume":"19","author":"SJ Snedecor","year":"2019","unstructured":"Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infect Dis. 2019;19(1):484. https:\/\/doi.org\/10.1186\/s12879-019-3975-6.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"681_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12879-021-05850-0","volume":"21","author":"K Nickel","year":"2021","unstructured":"Nickel K, Halfpenny NJA, Snedecor SJ, Punekar YS. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infect Dis. 2021;21(1):222. https:\/\/doi.org\/10.1186\/s12879-021-05850-0.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"681_CR31","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/jac\/dky566","volume":"74","author":"A d\u2019Arminio Monforte","year":"2019","unstructured":"d\u2019Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, et al. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019;74(5):1363\u20137. https:\/\/doi.org\/10.1093\/jac\/dky566.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"681_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40121-019-00274-5","volume":"9","author":"AM Mills","year":"2020","unstructured":"Mills AM, Brunet L, Fusco JS, et al. Virologic outcomes among ART-naive individuals initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: an Observational Study. Infect Dis Ther. 2020;9(1):41\u201352. https:\/\/doi.org\/10.1007\/s40121-019-00274-5.","journal-title":"Infect Dis Ther"},{"issue":"32","key":"681_CR33","doi-asserted-by":"publisher","first-page":"e16721","DOI":"10.1097\/MD.0000000000016721","volume":"98","author":"TT Brehm","year":"2019","unstructured":"Brehm TT, Franz M, Hufner A, et al. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naive and -experienced patients. Medicine. 2019;98(32):e16721. https:\/\/doi.org\/10.1097\/MD.0000000000016721.","journal-title":"Medicine"},{"issue":"2","key":"681_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/25787489.2021.1941672","volume":"22","author":"F Spinelli","year":"2021","unstructured":"Spinelli F, Prakash M, Slater J, et al. Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials. HIV Res Clin Pract. 2021;22(2):46\u201354. https:\/\/doi.org\/10.1080\/25787489.2021.1941672.","journal-title":"HIV Res Clin Pract"},{"issue":"1","key":"681_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/hiv.13319","volume":"24","author":"F Maggiolo","year":"2023","unstructured":"Maggiolo F, Rizzardini G, Molina JM, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age. HIV Med. 2023;24(1):27\u201336. https:\/\/doi.org\/10.1111\/hiv.13319.","journal-title":"HIV Med"},{"issue":"2","key":"681_CR36","doi-asserted-by":"publisher","first-page":"e25449","DOI":"10.1002\/jia2.25449","volume":"23","author":"D Back","year":"2020","unstructured":"Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23(2):e25449. https:\/\/doi.org\/10.1002\/jia2.25449.","journal-title":"J Int AIDS Soc"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00681-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-024-00681-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00681-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T10:03:11Z","timestamp":1734775391000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-024-00681-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1186\/s12981-024-00681-w","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work uses data provided by patients and collected by the VA as part of their care and support. The VACS study was approved by the institutional review boards of Yale University (ref Yale: 0309025943) and VA Connecticut Healthcare System (ref VA: AJ0001). It has been granted a waiver of informed consent and is compliant with the Health Insurance Portability and Accountability Act.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ViiV Healthcare contributed to the design of the study, interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Authors who are VA employees participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funder\/sponsor"}},{"value":"The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"CEH., CH., and VV. are employed by ViiV Healthcare. VCM has received investigator-initiated research grants (to the institution) and consultation fees from Eli Lilly, Bayer, Gilead Sciences, Merck, and ViiV. LY, KG, ACJ, and MA report no conflicts of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}